Oryzon Genomics S.A. (ORYZF)
USD 3.03
(-0.66%)
USD 3.03
(-0.66%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.54 Million EUR | 17.14% |
| 2022 | -5.48 Million EUR | 21.69% |
| 2021 | -7.01 Million EUR | -63.26% |
| 2020 | -4.29 Million EUR | -11.85% |
| 2019 | -3.83 Million EUR | -31.65% |
| 2018 | -2.91 Million EUR | 32.56% |
| 2017 | -4.32 Million EUR | 5.54% |
| 2016 | -4.57 Million EUR | -1865.23% |
| 2015 | -232.93 Thousand EUR | -103.8% |
| 2014 | 6.12 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -3.49 Million USD | -132.12% |
| 2024 Q2 | -3311.12 EUR | 127.72% |
| 2024 Q3 | -2.79 Million EUR | -434.31% |
| 2023 Q3 | -779.26 Thousand EUR | 35.17% |
| 2023 Q2 | -1.2 Million EUR | 5.28% |
| 2023 Q1 | -1.26 Million EUR | -112.77% |
| 2023 FY | -4.54 Million EUR | 17.14% |
| 2023 Q4 | -1.29 Million EUR | -66.68% |
| 2022 Q1 | -1.74 Million EUR | -131.32% |
| 2022 Q2 | 1.69 Million EUR | 197.2% |
| 2022 FY | -5.48 Million EUR | 21.69% |
| 2022 Q3 | -5.01 Million USD | -396.33% |
| 2022 Q4 | 9.93 Million EUR | 297.95% |
| 2021 Q2 | -1.57 Million EUR | 66.91% |
| 2021 FY | -7.01 Million EUR | -63.26% |
| 2021 Q3 | -4.35 Million USD | -176.57% |
| 2021 Q1 | -4.75 Million EUR | -367.87% |
| 2021 Q4 | 5.56 Million USD | 227.72% |
| 2020 Q2 | -1.18 Million EUR | -12.85% |
| 2020 FY | -4.29 Million EUR | -11.85% |
| 2020 Q4 | -1.01 Million EUR | 2.74% |
| 2020 Q3 | -1.04 Million EUR | 11.56% |
| 2020 Q1 | -1.04 Million EUR | -53.32% |
| 2019 Q2 | -1.36 Million EUR | -54.64% |
| 2019 Q1 | -879.91 Thousand EUR | -46.84% |
| 2019 Q4 | -683.59 Thousand EUR | 25.31% |
| 2019 FY | -3.83 Million EUR | -31.65% |
| 2019 Q3 | -915.19 Thousand EUR | 32.74% |
| 2018 FY | -2.91 Million EUR | 32.56% |
| 2018 Q2 | -849.79 Thousand EUR | -37.29% |
| 2018 Q3 | -848.27 Thousand EUR | 0.18% |
| 2018 Q4 | -599.22 Thousand EUR | 29.36% |
| 2018 Q1 | -618.99 Thousand EUR | 45.88% |
| 2017 Q4 | -1.14 Million EUR | -11.8% |
| 2017 Q2 | -1.21 Million EUR | -29.78% |
| 2017 Q1 | -938.84 Thousand EUR | 18.87% |
| 2017 FY | -4.32 Million EUR | 5.54% |
| 2017 Q3 | -1.02 Million EUR | 16.03% |
| 2016 Q2 | -1.65 Million EUR | -151.06% |
| 2016 FY | -4.57 Million EUR | -1865.23% |
| 2016 Q1 | -658.1 Thousand EUR | -23.65% |
| 2016 Q4 | -1.15 Million EUR | -4.23% |
| 2016 Q3 | -1.11 Million EUR | 32.81% |
| 2015 Q3 | -270.46 Thousand EUR | -124.11% |
| 2015 Q4 | -532.23 Thousand EUR | -96.79% |
| 2015 FY | -232.93 Thousand EUR | -103.8% |
| 2015 Q1 | -551.99 Thousand EUR | 0.0% |
| 2015 Q2 | 1.12 Million EUR | 303.22% |
| 2014 FY | 6.12 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | -19.084% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 93.663% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1638.151% |
| SQZ Biotechnologies Company | -75.82 Million USD | 94.0% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -59.592% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 74.51% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 105.558% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -196.162% |
| Marizyme, Inc. | -34.08 Million USD | 86.654% |
| Genus plc | 6.4 Million USD | 171.081% |
| Pharming Group N.V. | -4.87 Million USD | 6.77% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -129.008% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -388.436% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 45.519% |
| ContraFect Corporation | -56.88 Million USD | 92.003% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -224.481% |
| IMV Inc. | -38.67 Million USD | 88.236% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -65.375% |
| ONE Bio Corp. | 13.68 Million USD | 133.251% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 92.288% |
| Mesoblast Limited | -84.14 Million USD | 94.594% |
| MultiCell Technologies, Inc. | -722.81 USD | -629276.046% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 228.508% |
| Genscript Biotech Corporation | -415.79 Million USD | 98.906% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -1067.747% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -73.136% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 192.561% |
| Biomind Labs Inc. | -1 Million USD | -350.592% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -56.801% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 31.571% |
| Skye Bioscience, Inc. | -13.67 Million USD | 66.726% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -144.007% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 146.695% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -15088.278% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 0.121% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 9.818% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 71.334% |
| Accustem Sciences Inc. | -3.74 Million USD | -21.428% |
| EV Biologics, Inc. | -483.06 Thousand USD | -841.741% |
| Q BioMed Inc. | -3.44 Million USD | -32.028% |
| GB Sciences, Inc. | -1.42 Million USD | -220.251% |
| Alpha Cognition Inc. | -9.7 Million USD | 53.128% |
| CSL Limited | 3.7 Billion USD | 100.123% |
| Agentix Corp. | -1.37 Million USD | -231.633% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 91.725% |
| Enzolytics Inc. | -2.14 Million USD | -111.709% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -12.74 Million USD | 64.317% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -43.586% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -135.391% |
| argenx SE | -425.04 Million USD | 98.93% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 91.804% |
| HST Global, Inc. | -140.9 Thousand USD | -3128.507% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -335.746% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -304.407% |
| Halberd Corporation | -75.05 Thousand USD | -5961.55% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -55.824% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -33.604% |
| Zenith Capital Corp. | -8.94 Million USD | 49.131% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -188.041% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -85.279% |
| AVAX Technologies, Inc. | 6.69 Million USD | 167.971% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -2552.443% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -126.92% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -26013.271% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | -84.42% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -362.291% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -262.197% |
| Kadimastem Ltd | -3.04 Million USD | -49.632% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 41.519% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -2406.65% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -240.654% |
| LadRx Corporation | -3.82 Million USD | -18.976% |
| Cell Source, Inc. | -4.32 Million USD | -5.175% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -994.927% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -562.231% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -562.231% |
| Affymax, Inc. | -15.04 Million USD | 69.765% |
| Mobile Lads Corp. | -554.55 Thousand USD | -720.34% |
| Itoco Inc. | -919.14 Thousand USD | -394.94% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -7.332% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -306.541% |
| International Stem Cell Corporation | -663 Thousand USD | -586.153% |
| CytoDyn Inc. | -18.05 Million USD | 74.808% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -17973.87% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1967.082% |
| Qrons Inc. | -643.67 Thousand USD | -606.751% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -705.562% |
| SYBLEU INC | -149.18 Thousand USD | -2949.466% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -104.011% |
| Rebus Holdings, Inc. | -664 Thousand USD | -585.119% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -150.462% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -8542.084% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -22265.747% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 87.456% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -181.161% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -518.235% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -46.229% |
| Neutra Corp. | -229.48 Thousand USD | -1882.34% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 74.062% |
| PureTech Health plc | -146.19 Million USD | 96.888% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 78.832% |
| IXICO plc | -1.43 Million USD | -216.576% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 52.068% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 96.265% |
| CSL Limited | 3.81 Billion USD | 100.119% |
| Cellectis S.A. | -108.85 Million USD | 95.821% |